MedTrace Logo

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

NCT06793371 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-12

No results posted yet for this study

Summary

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

Conditions

  • Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Interventions

DRUG

CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

CK-4021586 administered orally

DRUG

Placebo to match CK-4021586

Placebo administered orally

Sponsors & Collaborators

  • Cytokinetics

    lead INDUSTRY

Principal Investigators

  • Cytokinetics MD · Cytokinetics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-06
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06793371 on ClinicalTrials.gov